<DOC>
	<DOC>NCT01343823</DOC>
	<brief_summary>A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.</brief_summary>
	<brief_title>Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Males and females 18 years of age or older Must currently be on ACE inhibitor therapy and have received a dose within 36 hours Presenting with ACEIA of the head/neck region within 12 hours after onset All females must have a negative urine pregnancy test prior to administration of the study drug. Those who have had a total hysterectomy, bilateral oophorectomy or are two years postmenopausal do not require a pregnancy test. Hypersensitivity to ecallantide Pregnancy or breast feeding Patients who have had angioedema and were not concurrently on an ACE inhibitor Patients exhibiting urticaria Patients who are intubated or who have a tracheostomy related to the current episode of angioedema Opinion of the investigator that the patient would not be a good candidate Participation in another investigational study within 30 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>